{"id":1605,"date":"2023-11-10T23:39:05","date_gmt":"2023-11-10T23:39:05","guid":{"rendered":"https:\/\/mm713.org\/?p=1605"},"modified":"2023-12-04T18:02:42","modified_gmt":"2023-12-04T18:02:42","slug":"future-for-patients-with-transthyretin-cardiac-amyloidosis","status":"publish","type":"post","link":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/","title":{"rendered":"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter"},"content":{"rendered":"<p>The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today\u2019s clinical trials, providers are optimistic that the expansion of options for patient care will continue.<\/p>\n<p>The future is indeed looking brighter.<\/p>\n<p><iframe title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/TmKWdwd1l2o?si=SaXCnJYV7L2W4c8Q\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1852,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[13,250,16,18],"tags":[30,31,141,223,224,225,21,24,29],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter - Mackenzie&#039;s Mission<\/title>\n<meta name=\"description\" content=\"The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today\u2019s clinical trials, providers are optimistic that the expansion of options for patient care will continue. The future is indeed looking brighter.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter - Mackenzie&#039;s Mission\" \/>\n<meta property=\"og:description\" content=\"The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today\u2019s clinical trials, providers are optimistic that the expansion of options for patient care will continue. The future is indeed looking brighter.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Mackenzie&#039;s Mission\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-10T23:39:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-04T18:02:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mm713.org\/wp-content\/uploads\/2023\/11\/Future-for-Patients-with-Transthyretin-Cardiac-Amyloidosis-is-Looking-Brighter-Mat-Maurer.png\" \/>\n\t<meta property=\"og:image:width\" content=\"940\" \/>\n\t<meta property=\"og:image:height\" content=\"788\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"anarmandakh\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"anarmandakh\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/\"},\"author\":{\"name\":\"anarmandakh\",\"@id\":\"https:\/\/mm713.org\/#\/schema\/person\/32be5a9c60a0c1df2c1beb0fdeab9d41\"},\"headline\":\"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter\",\"datePublished\":\"2023-11-10T23:39:05+00:00\",\"dateModified\":\"2023-12-04T18:02:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/\"},\"wordCount\":99,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/mm713.org\/#organization\"},\"keywords\":[\"hATTR\",\"familial amyloidosis\",\"Hereditary Amyloidosis\",\"wild-type\",\"ATTR\",\"transthyretin amyloidosis\",\"amyloidosis\",\"ATTRwt\",\"ATTRv\"],\"articleSection\":[\"Disease Overview\",\"Patients Edu Highlight\",\"Treatment\",\"Expert Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/\",\"url\":\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/\",\"name\":\"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter - Mackenzie&#039;s Mission\",\"isPartOf\":{\"@id\":\"https:\/\/mm713.org\/#website\"},\"datePublished\":\"2023-11-10T23:39:05+00:00\",\"dateModified\":\"2023-12-04T18:02:42+00:00\",\"description\":\"The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today\u2019s clinical trials, providers are optimistic that the expansion of options for patient care will continue. The future is indeed looking brighter.\",\"breadcrumb\":{\"@id\":\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/mm713.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mm713.org\/#website\",\"url\":\"https:\/\/mm713.org\/\",\"name\":\"Mackenzie&#039;s Mission\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/mm713.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mm713.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mm713.org\/#organization\",\"name\":\"Mackenzie&#039;s Mission\",\"url\":\"https:\/\/mm713.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mm713.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mm713.org\/wp-content\/uploads\/2023\/11\/Logo-Only.png\",\"contentUrl\":\"https:\/\/mm713.org\/wp-content\/uploads\/2023\/11\/Logo-Only.png\",\"width\":808,\"height\":572,\"caption\":\"Mackenzie&#039;s Mission\"},\"image\":{\"@id\":\"https:\/\/mm713.org\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/mm713.org\/#\/schema\/person\/32be5a9c60a0c1df2c1beb0fdeab9d41\",\"name\":\"anarmandakh\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mm713.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3866013792420336f14b9b0ae18480de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3866013792420336f14b9b0ae18480de?s=96&d=mm&r=g\",\"caption\":\"anarmandakh\"},\"sameAs\":[\"https:\/\/pixlinkstudio.com\/\"],\"url\":\"https:\/\/mm713.org\/author\/anarmandakh\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter - Mackenzie&#039;s Mission","description":"The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today\u2019s clinical trials, providers are optimistic that the expansion of options for patient care will continue. The future is indeed looking brighter.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/","og_locale":"en_US","og_type":"article","og_title":"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter - Mackenzie&#039;s Mission","og_description":"The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today\u2019s clinical trials, providers are optimistic that the expansion of options for patient care will continue. The future is indeed looking brighter.","og_url":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/","og_site_name":"Mackenzie&#039;s Mission","article_published_time":"2023-11-10T23:39:05+00:00","article_modified_time":"2023-12-04T18:02:42+00:00","og_image":[{"width":940,"height":788,"url":"https:\/\/mm713.org\/wp-content\/uploads\/2023\/11\/Future-for-Patients-with-Transthyretin-Cardiac-Amyloidosis-is-Looking-Brighter-Mat-Maurer.png","type":"image\/png"}],"author":"anarmandakh","twitter_card":"summary_large_image","twitter_misc":{"Written by":"anarmandakh","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#article","isPartOf":{"@id":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/"},"author":{"name":"anarmandakh","@id":"https:\/\/mm713.org\/#\/schema\/person\/32be5a9c60a0c1df2c1beb0fdeab9d41"},"headline":"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter","datePublished":"2023-11-10T23:39:05+00:00","dateModified":"2023-12-04T18:02:42+00:00","mainEntityOfPage":{"@id":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/"},"wordCount":99,"commentCount":0,"publisher":{"@id":"https:\/\/mm713.org\/#organization"},"keywords":["hATTR","familial amyloidosis","Hereditary Amyloidosis","wild-type","ATTR","transthyretin amyloidosis","amyloidosis","ATTRwt","ATTRv"],"articleSection":["Disease Overview","Patients Edu Highlight","Treatment","Expert Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/","url":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/","name":"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter - Mackenzie&#039;s Mission","isPartOf":{"@id":"https:\/\/mm713.org\/#website"},"datePublished":"2023-11-10T23:39:05+00:00","dateModified":"2023-12-04T18:02:42+00:00","description":"The treatment for patients with Transthyretin Cardiac Amyloidosis has advanced significantly since 2018 when there were no FDA-approved therapies. In this presentation, Dr. Mat Maurer from Columbia University shares how diagnostic imaging techniques have significantly improved, thereby reducing the need for an invasive heart biopsy. In addition, he shares fascinating statistics on how the age and stage of diagnosis has been evolving. Based on today\u2019s clinical trials, providers are optimistic that the expansion of options for patient care will continue. The future is indeed looking brighter.","breadcrumb":{"@id":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mm713.org\/future-for-patients-with-transthyretin-cardiac-amyloidosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mm713.org\/"},{"@type":"ListItem","position":2,"name":"Expert Insights: The Future for Patients with Transthyretin Cardiac Amyloidosis is Looking Brighter"}]},{"@type":"WebSite","@id":"https:\/\/mm713.org\/#website","url":"https:\/\/mm713.org\/","name":"Mackenzie&#039;s Mission","description":"","publisher":{"@id":"https:\/\/mm713.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mm713.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mm713.org\/#organization","name":"Mackenzie&#039;s Mission","url":"https:\/\/mm713.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mm713.org\/#\/schema\/logo\/image\/","url":"https:\/\/mm713.org\/wp-content\/uploads\/2023\/11\/Logo-Only.png","contentUrl":"https:\/\/mm713.org\/wp-content\/uploads\/2023\/11\/Logo-Only.png","width":808,"height":572,"caption":"Mackenzie&#039;s Mission"},"image":{"@id":"https:\/\/mm713.org\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/mm713.org\/#\/schema\/person\/32be5a9c60a0c1df2c1beb0fdeab9d41","name":"anarmandakh","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mm713.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3866013792420336f14b9b0ae18480de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3866013792420336f14b9b0ae18480de?s=96&d=mm&r=g","caption":"anarmandakh"},"sameAs":["https:\/\/pixlinkstudio.com\/"],"url":"https:\/\/mm713.org\/author\/anarmandakh\/"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/posts\/1605"}],"collection":[{"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/comments?post=1605"}],"version-history":[{"count":6,"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/posts\/1605\/revisions"}],"predecessor-version":[{"id":1942,"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/posts\/1605\/revisions\/1942"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/media\/1852"}],"wp:attachment":[{"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/media?parent=1605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/categories?post=1605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mm713.org\/wp-json\/wp\/v2\/tags?post=1605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}